Clearmind Medicine (NASDAQ:CMND) Posts Earnings Results

Posted by Kyle Jackson on Mar 12th, 2026

Clearmind Medicine (NASDAQ:CMND – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($3.32) earnings per share (EPS) for the quarter, FiscalAI reports.

Clearmind Medicine Stock Down 11.6%

Clearmind Medicine stock traded down $0.11 during mid-day trading on Thursday, hitting $0.83. 146,455 shares of the company’s stock were exchanged, compared to its average volume of 263,946. Clearmind Medicine has a fifty-two week low of $0.78 and a fifty-two week high of $52.40. The firm has a market capitalization of $1.24 million, a P/E ratio of -0.03 and a beta of 1.51. The company’s 50 day simple moving average is $1.78 and its 200-day simple moving average is $17.42.

Institutional Trading of Clearmind Medicine

An institutional investor recently raised its position in Clearmind Medicine stock. AdvisorShares Investments LLC raised its stake in Clearmind Medicine Inc. (NASDAQ:CMND – Free Report) by 9.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 224,378 shares of the company’s stock after buying an additional 18,445 shares during the quarter. AdvisorShares Investments LLC owned about 4.10% of Clearmind Medicine worth $230,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 96.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a research note on Saturday, December 20th.

Get Our Latest Stock Report on Clearmind Medicine

About Clearmind Medicine

(Get Free Report)

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.